StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) income statement

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30455% above fair value
$298.71+4.90 (+1.67%)

Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –

Ligand Pharmaceuticals Inc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
10.1%
Net margin
20.3%
Return on equity, FY2025
13.5%

Financial strength

Current ratio
1.22
Debt to equity
1.17
Debt to assets
50.4%
Cash to current liabilities
11.2%

Valuation

P/E ratio
130.4
Price to sales
23.54
Price to book
6.21
Dividend yield
–

See a number that looks wrong?